Login or sign up
For business

Oncotartis, inc.

4.2Β· 11 reviews
Average ratingGreat
4.2/ 5

Based on 11 reviews

536%
445%
318%
20%
10%
Ask AI

What reviewers say about Oncotartis, inc.

Based on 11 reviews, listing data and website checks Β· updated 5 days ago

Customers generally praise the quality of Oncotartis, Inc.’s products and its helpful, outstanding customer service, with many saying they would recommend the company or purchase again. They also find the website easy to navigate.
What is Oncotartis, inc.?

OncoTartis, Inc. is a private biotechnology company established in 2011 that develops a novel category of anti-cancer drugs directed against tissue-specific targets for a subset of cancers including breast, prostate, ovarian, melanoma and hematological malignancies. Its leading product OT-82 is a nicotinamide phosphoribosyltransferase (NAMPT) inhibitor being developed to treat Acute Myeloid Leukemia (AML), with an Investigational New Drug application (IND) planned for submission to the FDA in the fourth quarter of 2017. The company's founding IP originated from Prof. Andrei Gudkov's laboratory at Roswell Park Cancer Institute in Buffalo, NY.

Where is the business located and how long has it existed?

The company is located at 640 ellicott street in Buffalo, Missouri, and operates within the biotechnology industry. It has been in existence since 2011, making it a relatively recent entrant in the field of cancer drug development.

What is the current Trustburn rating and how recent are the reviews?

OncoTartis, Inc. currently holds a Trustburn rating of 4.2 out of 5 based on 11 reviews. The reviews are all from 2023, with the most recent dated October 15, 2023, and the oldest dated January 5, 2023.

What do reviewers say about the quality and service?

Reviewers consistently praise the excellent quality of the products and the top-notch customer service provided by the company. Multiple customers mention that the website is easy to navigate and the customer support is always helpful and outstanding.

How can visitors find more information about the company?

The company's website is oncotartis.com, and they have a LinkedIn profile at linkedin.com/company/oncotartis-inc-. These are the official channels listed for the business.

How can I contact Oncotartis, inc.?

You can reach Oncotartis, inc. by e-mail at info@oncotartis.com.

What is the official website of Oncotartis, inc.?

The official website of Oncotartis, inc. is oncotartis.com.

Is Oncotartis, inc. on social media?

Oncotartis, inc. has official profiles on Linkedin.

AI-generated from reviews on this page. Verify anything important with the company directly.

Leonora Balaj
Reviews 1

I am a customer and I have been using Oncotartis, inc. for a while now. I must say that their products are of great quality. The website is easy to navigate and the customer service is excellent. I highly recommend Oncotartis, inc. to anyone looking for high-quality products and great customer service.

News

No news yet. This is where the business shares its own updates and press.

Photos

No photos yet. Photos shared by reviewers will show up here.

Widgets

Boost your business trust by displaying a widget on your website β€” a simple way to convert your visitors into customers.

Get the widget for your site →

About Oncotartis, inc.

OncoTartis, Inc. is a private biotechnology company established in 2011. Company’s founding IP came from Prof. Andrei Gudkov’s laboratory at Roswell Park Cancer Institute (Buffalo, NY). OncoTartis develops a novel category of anti-cancer drugs directed against tissue-specific targets for a subset of cancers (breast, prostate, ovarian, melanoma and hematological malignancies). Its leading product OT-82 is a nicotinamide phosphoribosyltransferase (NAMPT) inhibitor being developed to treat Acute Myeloid Leukemia (AML). Investigational New Drug application (IND) will be submitted to FDA in the forth quarter of 2017.

Address
640 ellicott street
Categories
Biotechnology